Definium Therapeutics (DFTX) Change in Account Payables (2021 - 2026)

Definium Therapeutics (DFTX) has 6 years of Change in Account Payables data on file, last reported at $1.8 million in Q1 2026.

• On a quarterly basis, Change in Account Payables rose 589.92% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $4.9 million, a 243.89% increase from a year earlier, with the FY2025 full-year figure at $3.3 million, up 256.96% from the prior year.
• Change in Account Payables for Q1 2026 stood at $1.8 million, up from -$2.8 million in the prior quarter.
• Over the last five years, Change in Account Payables for DFTX reached as high as $6.3 million in Q2 2023 and fell as low as -$3.5 million in Q4 2023.
• Historically, Change in Account Payables has averaged $174117.6 across 5 years, with a median of $100000.0 in 2022.
• On a YoY basis, Change in Account Payables climbed as much as 829.78% in 2025 and fell as far as 1889.93% in 2025.
• Year by year, Change in Account Payables stood at $1.3 million in 2022, then tumbled by 375.73% to -$3.5 million in 2023, then jumped by 96.04% to -$139000.0 in 2024, then tumbled by 1889.93% to -$2.8 million in 2025, then surged by 164.35% to $1.8 million in 2026.
• Per Business Quant data, the three most recent Change in Account Payables figures were $1.8 million in Q1 2026, -$2.8 million in Q4 2025, and $3.9 million in Q3 2025.